Short-term biomarkers of cigarette smoke condensate tumor promoting potential in mouse skin.
Previous studies demonstrated that cigarette smoke condensates (CSCs) possessing significantly different tumorigenic potentials according to a standardized 30-week mouse skin tumor-promotion protocol could likewise be discriminated utilizing short-term indices of sustained hyperplasia and/or inflammation (G. M. Curtin et al., 2004, Toxicol. Sci. 81, 14-25). The current study employed a truncated initiation-promotion protocol to further evaluate CSC-induced hyperplasia, examining issues related to time course of induction, existence of a threshold and suitable dynamic range for detectable responses, and reversibility. Condensate application (9-36 mg "tar"/200-microl application, thrice-weekly for 3-15 weeks) induced treatment-related increases for epidermal thickness, proliferative index as assessed by 5-bromo-2'-deoxyuridine (BrdU) labeling, and ornithine decarboxylase (ODC) expression. Interestingly, observed increases for interfollicular BrdU labeling and ODC expression were partially reversed but still elevated upon cessation of promotion, while increases within the perifollicular epidermis remained elevated at a level similar to that observed during CSC application. In particular, assessments based on perifollicular ODC expression would appear to provide a greater opportunity for test article discrimination based on a rapid time to induction, a low threshold and expanded dynamic range of responses, and the potential to account for irreversible changes. These findings are particularly intriguing based on reports suggesting that ODC expression may be necessary for tumor promotion and that mouse skin tumors originate primarily within the perifollicular epidermis.
Curtin
Geoffrey M
GM
Research and Development, R. J. Reynolds Tobacco Company, Winston-Salem, North Carolina 27102, USA. curting@rjrt.com
Hanausek
Margaret
M
Walaszek
Zbigniew
Z
Zoltaszek
Robert
R
Swauger
James E
JE
Mosberg
Arnold T
AT
Slaga
Thomas J
TJ
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity; D000279:Administration, Cutaneous; D000818:Animals; D014408:Biomarkers, Tumor; D001973:Bromodeoxyuridine / Q000378:metabolism; D015197:Carcinogenicity Tests; D002273:Carcinogens / Q000737:chemistry / Q000633:toxicity*; D049109:Cell Proliferation / Q000187:drug effects; D003043:Cocarcinogenesis; D004305:Dose-Response Relationship, Drug; D005260:Female; D006965:Hyperplasia / Q000139:chemically induced; D051379:Mice; D018632:Mice, Inbred SENCAR; D009955:Ornithine Decarboxylase / Q000378:metabolism; D012867:Skin / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D012906:Smoke / Q000009:adverse effects*; D014026:Nicotiana / Q000737:chemistry / Q000633:toxicity*
D014408:Biomarkers, Tumor; D002273:Carcinogens; D012906:Smoke; D015127:9,10-Dimethyl-1,2-benzanthracene; D009955:Ornithine Decarboxylase; D001973:Bromodeoxyuridine